South Korea
· Delayed Price · Currency is KRW Pharmsville Statistics
Total Valuation
Pharmsville has a market cap or net worth of KRW 43.05 billion. The enterprise value is 3.37 billion.
| Market Cap | 43.05B |
| Enterprise Value | 3.37B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmsville has 7.73 million shares outstanding. The number of shares has decreased by -0.82% in one year.
| Shares Outstanding | 7.73M |
| Shares Change (YoY) | -0.82% |
| Shares Change (QoQ) | -0.89% |
| Owned by Insiders (%) | 80.39% |
| Owned by Institutions (%) | n/a |
| Float | 1.52M |
Valuation Ratios
The trailing PE ratio is 26.29.
| PE Ratio | 26.29 |
| Forward PE | n/a |
| PS Ratio | 2.27 |
| PB Ratio | 0.68 |
| P/FCF Ratio | 13.98 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.83, with an EV/FCF ratio of 1.09.
| EV / Earnings | 2.04 |
| EV / Sales | 0.18 |
| EV / EBITDA | 4.83 |
| EV / EBIT | 253.87 |
| EV / FCF | 1.09 |
Financial Position
The company has a current ratio of 9.23, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.23 |
| Quick Ratio | 8.60 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 1.61 |
| Debt / FCF | 0.36 |
| Interest Coverage | 0.16 |
Financial Efficiency
Return on equity (ROE) is 2.58% and return on invested capital (ROIC) is 0.01%.
| Return on Equity (ROE) | 2.58% |
| Return on Assets (ROA) | 0.01% |
| Return on Capital (ROIC) | 0.01% |
| Revenue Per Employee | 528.82M |
| Profits Per Employee | 45.75M |
| Employee Count | 36 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 2.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -38.62% |
| 50-Day Moving Average | 5,485.90 |
| 200-Day Moving Average | 6,605.83 |
| Relative Strength Index (RSI) | 59.81 |
| Average Volume (20 Days) | 24,560 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmsville had revenue of KRW 19.04 billion and earned 1.65 billion in profits. Earnings per share was 211.87.
| Revenue | 19.04B |
| Gross Profit | 11.50B |
| Operating Income | 13.26M |
| Pretax Income | 2.08B |
| Net Income | 1.65B |
| EBITDA | 696.66M |
| EBIT | 13.26M |
| Earnings Per Share (EPS) | 211.87 |
Balance Sheet
The company has 40.90 billion in cash and 1.12 billion in debt, giving a net cash position of 39.78 billion or 5,147.51 per share.
| Cash & Cash Equivalents | 40.90B |
| Total Debt | 1.12B |
| Net Cash | 39.78B |
| Net Cash Per Share | 5,147.51 |
| Equity (Book Value) | 63.45B |
| Book Value Per Share | 8,196.64 |
| Working Capital | 40.08B |
Cash Flow
In the last 12 months, operating cash flow was 3.22 billion and capital expenditures -141.01 million, giving a free cash flow of 3.08 billion.
| Operating Cash Flow | 3.22B |
| Capital Expenditures | -141.01M |
| Free Cash Flow | 3.08B |
| FCF Per Share | 398.57 |
Margins
Gross margin is 60.39%, with operating and profit margins of 0.07% and 8.65%.
| Gross Margin | 60.39% |
| Operating Margin | 0.07% |
| Pretax Margin | 10.92% |
| Profit Margin | 8.65% |
| EBITDA Margin | 3.66% |
| EBIT Margin | 0.07% |
| FCF Margin | 16.18% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.90%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.90% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 47.06% |
| Buyback Yield | 0.82% |
| Shareholder Yield | 2.72% |
| Earnings Yield | 3.80% |
| FCF Yield | 7.16% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmsville has an Altman Z-Score of 7.17.
| Altman Z-Score | 7.17 |
| Piotroski F-Score | n/a |